Marshall, Gerstein & Borun LLP advising CRISPR Therapeutics on intellectual property strategy

April 24, 2014

CRISPR Therapeutics, a biopharmaceutical company focused on the breakthrough gene-editing technology CRISPR-Cas9, recently announced its formation. It has raised $25 million in a series A investment and has a founding team of high-profile experts including Dr. Daniel Anderson, Dr. Emmanuelle Charpentier, Dr. Chad Cowan, Dr. Craig Mello, and Dr. Matthew Porteus. Marshall, Gerstein & Borun LLP has been advising CRISPR Therapeutics on intellectual property strategy.